Authentidate Holding Corp. Stock Surges On Investor Optimism (NASDAQ:ADAT)

Authentidate Holding Corp. (NASDAQ:ADAT)

As technology stocks guided the NASDAQ towards a 13 year high, let’s look at Authentidate Holding Corp. ticker symbol ADAT. The Stock has launched +31.32% Up 0.38 generating over 1.3 million shares in the financial markets Friday November 29, 2013. The Company (www.authentidate.com) specializes in secure web-based software applications and telehealth products and services for healthcare organizations. The  healthcare information technology market is estimated to reach $53.8 billion by the year 2014. So what’s hot about the stock you ask?

Authentidate Holding Corp. previously announced a $2.46 million private placement in Support of its anticipated growth opportunities. The Company recently reported increasing Q1 2013 revenue figures that were 96% greater when compared to the year last. The Y-O-Y and sequential revenue increases came from current operations primarily due to telehealth products and services, But the ace with a kicker is that, the Company has commenced enrolling patients for their Department of Veterans Affairs for telehealth pilot program for Human Immunodeficiency Virus. For these reason stated above, we believe that Authentidate Holding Corp is off to a great start this next coming quarter.

****

Durata Therapeutics, Inc. (NASDAQ:DRTX)

While we’re on the topic of health care, take a look at Durata Therapeutics ticker symbol DRTX. This publicly traded bio pharmaceutical company targets infectious diseases and illnesses with therapeutic treatments. In the financial markets, Durata Therapeutics has surged +5.75% Up 0.67 generating over 165 thousand shares in play Friday November 29, 2013. What’s makes this Company’s (www.duratatherapeutics.com) stock a hot topic of choice? The Answer is Dalvance(TM) (dalbavancin hydrochlorid).

The FDA accepted a New Drug Application concerning Dalvance(TM). Turns out that Dalvance(TM) has been accepted for the purpose of treating acute bacterial skin and skin structure infections. The global skin structure infection therapeutics market is estimated to reach over $1.57 billion in 2013. Once again, with the Affordable Care Act taking stage next year Dalvance(TM) technology has potential to become a clinical standard of care in hospital and ambulatory situations.

 Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://pennyotcstock.com/disclaimer/